Get the Stockscreener App
48.20
0.56%
-0.27
After Hours:
48.01
-0.19
-0.39%
Halozyme Therapeutics Inc stock is traded at $48.20, with a volume of 695.22K.
It is down -0.56% in the last 24 hours and down -4.82% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$48.47
Open:
$48.3
24h Volume:
695.22K
Relative Volume:
0.43
Market Cap:
$6.13B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
25.64
EPS:
1.88
Net Cash Flow:
$392.71M
1W Performance:
-1.63%
1M Performance:
-4.82%
6M Performance:
+12.72%
1Y Performance:
+25.19%
1-Day Range:
$48.12
$48.81
1-Week Range:
$46.27
$50.00
52-Week Range:
$33.15
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
48.20 | 6.13B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Hantz Financial Services Inc. Buys New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
CreativeOne Wealth LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Townsquare Capital LLC Purchases 44,044 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Halozyme abandons Evotec bid - Speciality Chemicals Magazine
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Glenmede Trust Co. NA - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Seems To Use Debt Rather Sparingly - Simply Wall St
Fisher Asset Management LLC Has $18.55 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
32,942 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by RPg Family Wealth Advisory LLC - MarketBeat
Halozyme to Present at Upcoming Investor Conferences - Quantisnow
Swedbank AB Decreases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Charles Schwab Investment Management Inc. Trims Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme: Growth Amid Uncertainty After Failed Acquisition (Rating Downgrade) (HALO) - Seeking Alpha
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up - MSN
Halozyme abandons its €2bn pursuit of Evotec - pharmaphorum
Intech Investment Management LLC Buys 33,542 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme eyes continuous manufacturing platform in $2.1bn Evotec bid - BioProcess Insider
Halozyme withdraws $2.1 billion buyout offer for Evotec - MSN
Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.11 - MarketBeat
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - MSN
Halozyme Therapeutics (NASDAQ:HALO) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Where are the Opportunities in (HALO) - Stock Traders Daily
Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal - MSN
BRIEF—Halozyme withdraws non-binding offer for Evotec - The Pharma Letter
Halozyme ends bid to acquire Evotec at €2 billion valuation By Investing.com - Investing.com Australia
San Diego’s Halozyme withdraws $2.1B Evotec bid, just one week after making offer - The San Diego Union-Tribune
Halozyme Withdraws Proposal To Buy Evotec, Citing ‘Unwillingness To Engage’ - Citeline
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why - MSN
Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook - AOL
Halozyme Pulls €2B Bid After Evotec Fails To Engage In Talks - Law360
Halozyme withdraws $2.1 bln buyout offer for German drug developer Evotec - Reuters
Evotec SE (EVO) Comment on Withdrawn Non-Binding Offer from Halozyme (HALO) - StreetInsider.com
Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy - TipRanks
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com India
Evotec plummetsHalozyme withdraws purchase bid - Marketscreener.com
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance
Halozyme Withdraws Bid For Evotec - Contract Pharma
Halozyme stock gains after pulling Evotec bid (HALO:NASDAQ) - Seeking Alpha
Halozyme Withdraws Bid to Purchase Drug Developer Evotec - Bloomberg
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions - PR Newswire
B. Metzler seel. Sohn & Co. Holding AG Invests $1.90 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial - Yahoo Finance
Thrivent Financial for Lutherans Has $13.34 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Natixis Advisors LLC Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
It has been confirmed that Merck (MSD), a large global pharmaceutical company, has filed a patent in.. - 매일경제
San Diego biotech Halozyme makes $2.1B bid for German drugmaker - The San Diego Union-Tribune
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Aurora Investment Counsel - MarketBeat
Segall Bryant & Hamill LLC Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery - MSN
Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views - Benzinga
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - MSN
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):